[go: up one dir, main page]

AR110590A1 - Activador de nrf2 - Google Patents

Activador de nrf2

Info

Publication number
AR110590A1
AR110590A1 ARP170103684A ARP170103684A AR110590A1 AR 110590 A1 AR110590 A1 AR 110590A1 AR P170103684 A ARP170103684 A AR P170103684A AR P170103684 A ARP170103684 A AR P170103684A AR 110590 A1 AR110590 A1 AR 110590A1
Authority
AR
Argentina
Prior art keywords
alkyl
membered
alkynyl
alkenyl
carbocyclyl
Prior art date
Application number
ARP170103684A
Other languages
English (en)
Inventor
Vloten Kurt D Van
John H Jones
Teyu Chen
Istvan Enyedy
Zhili Xin
Andrew George Capacci
Edward Yin Lin
- Lucas Brian Stuart Shiang
Original Assignee
Biogen Ma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Ma Inc filed Critical Biogen Ma Inc
Publication of AR110590A1 publication Critical patent/AR110590A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/04—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/08—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with a hetero atom directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
    • C07D217/18—Aralkyl radicals
    • C07D217/20—Aralkyl radicals with oxygen atoms directly attached to the aromatic ring of said aralkyl radical, e.g. papaverine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/16—Benzazepines; Hydrogenated benzazepines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/74—Benzo[b]pyrans, hydrogenated in the carbocyclic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/76—Benzo[c]pyrans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se proporcionan compuestos, sales farmacéuticamente aceptables de estos, métodos para su uso y producción. Reivindicación 1: Un compuesto representado por la fórmula (1), o una sal farmacéuticamente aceptable de este, donde R¹ es -CN, -C(O)Rᵃ, CH₃S(O)₂- o alquilo C₁₋₈ sustituido con uno o más átomos de flúor; Rᵃ es H, alquilo C₁₋₁₂, alquenilo C₂₋₁₂, alquinilo C₂₋₁₂, un carbociclilo de 3 a 12 miembros, un heterociclilo de 3 a 12 miembros, -OR¹¹, -SR¹⁴, -N(R¹²)₂, -NR¹³OR¹³, -NR¹³S(O)₂R¹³, -NR¹³C(O)R¹³, -N(R¹³)N(R¹³)₂, -N(R¹³)C(O)OR¹³ o -N(R¹³)C(O)N(R¹³)₂, donde cada uno del alquilo C₁₋₁₂, alquenilo C₂₋₁₂, alquinilo C₂₋₁₂, el carbociclilo de 3 a 12 miembros y el heterociclilo de 3 a 12 miembros se sustituye opcionalmente con uno o más de R²¹; R² es H, halo, -NO₂, -CN, -N₃, alquilo C₁₋₁₂, alquenilo C₂₋₁₂, alquinilo C₂₋₁₂, un carbociclilo de 3 a 12 miembros, un heterociclilo de 3 a 12 miembros, -C(O)R¹³, -C(S)R¹³, -C(O)OR¹³, -C(S)SR¹³, -C(O)SR¹³, -C(S)OR¹³, -SC(O)R¹³, -OC(S)R¹³, -SC(S)R¹³, -C(O)N(R¹³)₂, -OR¹¹, -SR¹⁴, -N(R¹²)₂, -N(R¹³)OR¹³, -N(R¹³)S(O)₂R¹³, -N(R¹³)C(O)R¹³, -N(R¹³)N(R¹³)₂, -N(R¹³)C(O)OR¹³, -N(R¹³)C(O)N(R¹³)₂, -S(O)₂R¹³, -S(O)R¹³, -S(O)N(R¹³)₂, -S(O)₂N(R¹³)₂, N⁺(R¹³)₃, -S⁺(R¹³)₂ o -Si(R¹³)₃, donde cada uno del alquilo C₁₋₁₂, alquenilo C₂₋₁₂, alquinilo C₂₋₁₂, carbociclilo de 3 a 12 miembros y heterociclilo de 3 a 12 miembros se sustituye opcionalmente con uno o más R²¹; R³ᵃ es H, alquilo C₁₋₁₂, alquenilo C₂₋₁₂, alquinilo C₂₋₁₂, un carbociclilo de 3 a 12 miembros, un heterociclilo de 3 a 12 miembros, -C(O)R¹³, -C(O)OR¹³, -C(O)N(R¹³)₂, -OR¹¹, -N(R¹²)₂, -N(R¹³)OR¹³, -N(R¹³)S(O)₂R¹³, -N(R¹³)C(O)R¹³, -N(R¹³)N(R¹³)₂, -N(R¹³)C(O)OR¹³, -N(R¹³)C(O)N(R¹³)₂, -S(O)R¹³, -S(O)N(R¹³)₂ o -S(O)₂N(R¹³)₂, donde cada uno del alquilo C₁₋₁₂, alquenilo C₂₋₁₂, alquinilo C₂₋₁₂, carbociclilo de 3 a 12 miembros y heterociclilo de 3 a 12 miembros se sustituye opcionalmente con uno o más R²¹; y R³ᵇ es alquilo C₁₋₁₂, alquenilo C₂₋₁₂, alquinilo C₂₋₁₂, un carbociclilo de 3 a 12 miembros, un heterociclilo de 3 a 12 miembros, -C(O)R¹³, -C(O)OR¹³, -C(O)N(R¹³)₂, -OR¹¹, -N(R¹²)₂, -N(R¹³)OR¹³, -N(R¹³)S(O)₂R¹³, -N(R¹³)C(O)R¹³, -N(R¹³)N(R¹³)₂, -N(R¹³)C(O)OR¹³, -N(R¹³)C(O)N(R¹³)₂, -S(O)R¹³, -S(O)N(R¹³)₂ o -S(O)₂N(R¹³)₂, donde cada uno del alquilo C₁₋₁₂, alquenilo C₂₋₁₂, alquinilo C₂₋₁₂, carbociclilo de 3 a 12 miembros y heterociclilo de 3 a 12 miembros se sustituye opcionalmente con uno o más R²¹; o R³ᵃ y R³ᵇ se toman juntos y son alquileno C₂₋₁₂, alquenileno C₂₋₁₂ o alquinileno C₂₋₁₂; donde cada uno del alquileno C₂₋₁₂, alquenileno C₂₋₁₂, alquinileno C₂₋₁₂ y carbociclilo de 3 - 6 miembros se sustituyen opcionalmente con uno o más R²¹; R⁴ es H, halo, -NO₂, -CN, -N₃, alquilo C₁₋₁₂, alquenilo C₂₋₁₂, alquinilo C₂₋₁₂, un carbociclilo de 3 a 12 miembros, un heterociclilo de 3 a 12 miembros, -C(O)R¹³, -C(S)R¹³, -C(O)OR¹³, -C(S)SR¹³, -C(O)SR¹³, -C(S)OR¹³, -SC(O)R¹³, -OC(S)R¹³, -SC(S)R¹³, -C(O)N(R¹³)₂, -OR¹¹, -SR¹⁴, -N(R¹²)₂, -N(R¹³)OR¹³, -N(R¹³)S(O)₂R¹³, -N(R¹³)C(O)R¹³, -N(R¹³)N(R¹³)₂, -N(R¹³)C(O)OR¹³, -N(R¹³)C(O)N(R¹³)₂, -S(O)₂R¹³, -S(O)R¹³, -S(O)N(R¹³)₂, -S(O)₂N(R¹³)₂, -N⁺(R¹³)₃, -S⁺(R¹³)₂ o -Si(R¹³)₃, donde cada uno del alquilo C₁₋₁₂, alquenilo C₂₋₁₂, alquinilo C₂₋₁₂, carbociclilo de 3 a 12 miembros y heterociclilo de 3 a 12 miembros se sustituye opcionalmente con uno o más R²¹; «⁻ ⁻ ⁻ ⁻ ⁻ ⁻» es un enlace simple o un enlace doble, donde cuando «⁻ ⁻ ⁻ ⁻ ⁻ ⁻» es un enlace doble, entonces R⁵ se encuentra ausente; y cuando «⁻ ⁻ ⁻ ⁻ ⁻ ⁻» es un enlace simple, entonces R⁵ es H, halo, -NO₂, -CN, -N₃, alquilo C₁₋₁₂, alquenilo C₂₋₁₂, alquinilo C₂₋₁₂, un carbociclilo de 3 a 12 miembros, un heterociclilo de 3 a 12 miembros, -C(O)R¹³, -C(S)R¹³, -C(O)OR¹³, -C(S)SR¹³, -C(O)SR¹³, -C(S)OR¹³, -SC(O)R¹³, -OC(S)R¹³, -SC(S)R¹³, -C(O)N(R¹³)₂, -OR¹¹, -SR¹⁴, -N(R¹²)₂, -N(R¹³)OR¹³, -N(R¹³)S(O)₂R¹³, -N(R¹³)C(O)R¹³, -N(R¹³)N(R¹³)₂, -N(R¹³)C(O)OR¹³, -N(R¹³)C(O)N(R¹³)₂, -S(O)₂R¹³, -S(O)R¹³, -S(O)N(R¹³)₂, -S(O)₂N(R¹³)₂, -N⁺(R¹³)₃, -S⁺(R¹³)₂ o -Si(R¹³)₃, donde cada uno del alquilo C₁₋₁₂, alquenilo C₂₋₁₂, alquinilo C₂₋₁₂, carbociclilo de 3 a 12 miembros y heterociclilo de 3 a 12 miembros se sustituye opcionalmente con uno o más R²¹; o R⁵ y R³ᵇ se toman junto con los carbonos con los que se acopla cada uno para formar un carbociclilo de 3 - 6 miembros, donde el carbociclilo de 3 - 6 miembros se sustituye opcionalmente con uno o más R²¹; R⁶, en cada aparición, es independientemente halo, -NO₂, -CN, -N₃, alquilo C₁₋₁₂, alquenilo C₂₋₁₂, alquinilo C₂₋₁₂, un carbociclilo de 3 a 12 miembros, un heterociclilo de 3 a 12 miembros, -C(O)R¹³, -C(S)R¹³, -C(O)OR¹¹, -C(S)SR¹³, -C(O)SR¹³, -C(S)OR¹³, -SC(O)R¹³, -OC(S)R¹³, -SC(S)R¹³, -C(O)N(R¹¹)₂, -OR¹¹, -SR¹⁴, -N(R¹²)₂, -N(R¹³)OR¹³, -N(R¹³)S(O)₂R¹³, -N(R¹³)C(O)R¹³, -N(R¹³)N(R¹³)₂, -N(R¹³)C(O)OR¹³, -N(R¹³)C(O)N(R¹³)₂, -S(O)₂R¹³, -S(O)R¹³, -S(O)N(R¹³)₂, -S(O)₂N(R¹³)₂, -N⁺(R¹³)₃, -S⁺(R¹³)₂ o -Si(R¹³)₃; o dos R⁶ unidos al mismo carbono del anillo para formar un oxo, =NR¹⁴ o alquilideno C₁₋₁₂, donde cada uno del alquilo C₁₋₁₂, alquenilo C₂₋₁₂, alquinilo C₂₋₁₂, carbociclilo de 3 a 12 miembros, heterociclilo de 3 a 12 miembros y alquilideno C₁₋₁₂ se sustituye opcionalmente con uno o más R²¹; X es NRᵇ u O; Rᵇ es H, alquilo C₁₋₁₂, alquenilo C₂₋₁₂, alquinilo C₂₋₁₂, un carbociclilo de 3 a 12 miembros, un heterociclilo de 3 a 12 miembros, -C(O)Rᶜ, -C(O)ORᶜ, -C(O)NRᶜRᶜ, -S(O)₂Rᶜ, -S(O)₂ORᶜ o -S(O)₂NRᶜRᶜ, donde cada uno del alquilo C₁₋₁₂, alquenilo C₂₋₁₂, alquinilo C₂₋₁₂, carbociclilo de 3 a 12 miembros y heterociclilo de 3 a 12 miembros se sustituye opcionalmente con uno o más R²¹; Rᶜ, en cada aparición, se selecciona independientemente de H, alquilo C₁₋₁₂, alquenilo C₂₋₁₂, alquinilo C₂₋₁₂, un carbociclilo de 3 a 12 miembros y un heterociclilo de 3 a 12 miembros, donde cada uno del alquilo C₁₋₁₂, alquenilo C₂₋₁₂, alquinilo C₂₋₁₂, carbociclilo de 3 a 12 miembros y heterociclilo de 3 a 12 miembros se sustituye opcionalmente con uno o más R²¹; R¹¹, en cada aparición, se selecciona independientemente de H, alquilo C₁₋₁₂, alquenilo C₂₋₁₂, alquinilo C₂₋₁₂, un carbociclilo de 3 a 12 miembros, un heterociclilo de 3 a 12 miembros, acilo C₁₋₁₂ y -Si(R¹³)₃, donde cada uno del alquilo C₁₋₁₂, alquenilo C₂₋₁₂, alquinilo C₂₋₁₂, carbociclilo de 3 a 12 miembros, heterociclilo de 3 a 12 miembros y acilo C₁₋₁₂ se sustituye opcionalmente con uno o más R²¹; R¹², en cada aparición, se selecciona independientemente de H, alquilo C₁₋₁₂, alcoxi C₁₋₁₂, alquenilo C₂₋₁₂, alquinilo C₂₋₁₂, un carbociclilo de 3 a 12 miembros, un heterociclilo de 3 a 12 miembros y -Si(R¹³)₃, donde cada uno del alquilo C₁₋₁₂, alcoxi C₁₋₁₂, alquenilo C₂₋₁₂, alquinilo C₂₋₁₂, carbociclilo de 3 a 12 miembros y heterociclilo de 3 a 12 miembros se sustituye opcionalmente con uno o más R²¹; R¹³, en cada aparición, se selecciona independientemente de H, alquilo C₁₋₁₂, alquenilo C₂₋₁₂, alquinilo C₂₋₁₂, un carbociclilo de 3 a 12 miembros y un heterociclilo de 3 a 12 miembros, donde cada uno del alquilo C₁₋₁₂, alquenilo C₂₋₁₂, alquinilo C₂₋₁₂, carbociclilo de 3 a 12 miembros y heterociclilo de 3 a 12 miembros se sustituye opcionalmente con uno o más R²¹; R¹⁴, en cada aparición, se selecciona independientemente de H, alquilo C₁₋₁₂, alquenilo C₂₋₁₂, alquinilo C₂₋₁₂, un carbociclilo de 3 a 12 miembros, un heterociclilo de 3 a 12 miembros y acilo C₁₋₁₂, donde cada uno del alquilo C₁₋₁₂, alquenilo C₂₋₁₂, alquinilo C₂₋₁₂, carbociclilo de 3 a 12 miembros, heterociclilo de 3 a 12 miembros y acilo C₁₋₁₂ se sustituye opcionalmente con uno o más R²¹; R²¹, en cada aparición, se selecciona independientemente de halo, -OH, -S(O)₂R¹⁶, alquilo C₁₋₁₂, alquenilo C₂₋₁₂, alquinilo C₂₋₁₂, alcoxi C₁₋₁₂, un carbociclilo de 3 a 12 miembros y un heterociclilo de 3 a 12 miembros, donde cada uno del alquilo C₁₋₁₂, alquenilo C₂₋₁₂, alquinilo C₂₋₁₂, alcoxi C₁₋₁₂, carbociclilo de 3 a 12 miembros y heterociclilo de 3 a 12 miembros se sustituye opcionalmente con 1 a 3 grupos que se seleccionan de halo, -OH, alquilo C₁₋₄ y alcoxi C₁₋₄; R¹⁶, en cada aparición, se selecciona independientemente de H o alquilo C₁₋₁₂; n es 0 o un entero de 1 a 8; p es 0, 1 ó 2; y q es 1, 2 ó 3, siempre que la suma de p y q no sea 4 ni 5.
ARP170103684A 2016-12-27 2017-12-26 Activador de nrf2 AR110590A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662439289P 2016-12-27 2016-12-27

Publications (1)

Publication Number Publication Date
AR110590A1 true AR110590A1 (es) 2019-04-10

Family

ID=61007836

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP170103684A AR110590A1 (es) 2016-12-27 2017-12-26 Activador de nrf2

Country Status (21)

Country Link
US (2) US10968181B2 (es)
EP (2) EP3562816B1 (es)
JP (1) JP7088933B2 (es)
KR (1) KR20190111949A (es)
CN (1) CN110382475A (es)
AR (1) AR110590A1 (es)
AU (1) AU2017387070B2 (es)
BR (1) BR112019013341A2 (es)
CA (1) CA3048849A1 (es)
CL (1) CL2019001804A1 (es)
CO (1) CO2019008110A2 (es)
CR (1) CR20190344A (es)
EA (1) EA201991595A1 (es)
ES (1) ES2878102T3 (es)
IL (1) IL267692B (es)
JO (1) JOP20190163B1 (es)
MX (1) MX2019007826A (es)
PE (1) PE20191488A1 (es)
TW (1) TW201827406A (es)
UY (1) UY37551A (es)
WO (1) WO2018125880A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3870578T (pt) * 2018-10-22 2023-11-15 C4X Discovery Ltd Compostos terapêuticos
NZ776102A (en) 2018-12-05 2024-12-20 Scohia Pharma Inc Macrocyclic compound and use thereof
CN112679328B (zh) * 2019-10-17 2023-09-15 南京药石科技股份有限公司 一种3-三氟甲基-2-环己烯-1-酮的工业化生产方法
KR102664144B1 (ko) 2021-08-05 2024-05-10 주식회사 엘씨에스바이오텍 신규한 곡류 발효물, 그 곡류 발효물의 피부 보호 용도, 피부 유용 물질 스크리닝 방법 및 산화적 스트레스로 인한 피부 손상 예측 방법
WO2024091523A1 (en) * 2022-10-24 2024-05-02 2A Biosciences, Inc. Conformationally restricted phenethylamine analogs
CN119735636A (zh) * 2024-09-06 2025-04-01 五邑大学 一种四环肽中间体化合物及其制备方法和应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
JP2008110962A (ja) * 2006-08-02 2008-05-15 Santen Pharmaceut Co Ltd Ｎｒｆ２活性化物質を有効成分として含む角結膜障害の予防または治療剤
CN103588678A (zh) 2008-04-18 2014-02-19 里亚塔医药公司 包含抗炎症药效团的化合物以及使用方法
US9139592B2 (en) 2010-06-14 2015-09-22 Trt Pharma Inc. Modulators of Nrf2 and uses thereof
JP2014510064A (ja) 2011-02-25 2014-04-24 ザ ジョンズ ホプキンス ユニバーシティ Ｎｒｆ２活性剤としてのカルコン誘導体
US20170354639A1 (en) 2014-10-24 2017-12-14 Biogen Ma Inc. Diterpenoid derivatives and methods of use thereof
CN107709306A (zh) * 2015-06-15 2018-02-16 葛兰素史密斯克莱知识产权发展有限公司 Nrf2调节剂

Also Published As

Publication number Publication date
IL267692A (en) 2019-08-29
US20210340107A1 (en) 2021-11-04
JP2020503332A (ja) 2020-01-30
WO2018125880A1 (en) 2018-07-05
US10968181B2 (en) 2021-04-06
US20190345112A1 (en) 2019-11-14
UY37551A (es) 2018-07-31
AU2017387070B2 (en) 2022-03-24
IL267692B (en) 2021-09-30
EA201991595A1 (ru) 2020-01-27
EP3562816B1 (en) 2021-01-20
CL2019001804A1 (es) 2019-11-15
JOP20190163A1 (ar) 2019-06-27
CR20190344A (es) 2019-11-19
CA3048849A1 (en) 2018-07-05
BR112019013341A2 (pt) 2019-12-24
MX2019007826A (es) 2019-10-24
ES2878102T3 (es) 2021-11-18
TW201827406A (zh) 2018-08-01
AU2017387070A1 (en) 2019-08-15
JP7088933B2 (ja) 2022-06-21
EP3875450A1 (en) 2021-09-08
JOP20190163B1 (ar) 2023-09-17
EP3562816A1 (en) 2019-11-06
KR20190111949A (ko) 2019-10-02
CO2019008110A2 (es) 2019-08-20
PE20191488A1 (es) 2019-10-21
CN110382475A (zh) 2019-10-25
WO2018125880A8 (en) 2019-06-06

Similar Documents

Publication Publication Date Title
AR110590A1 (es) Activador de nrf2
CO2022008968A2 (es) Nuevos derivados de metilquinazolinona
AR116694A1 (es) COMPUESTOS AGONISTAS b DEL RECEPTOR DE LA HORMONA TIROIDEA
AR111407A1 (es) Compuestos inhibidores de ask1 y usos de los mismos
AR100233A1 (es) Composición de limpieza
AR111689A1 (es) Tienopiridinas y benzotiofenos útiles como inhibidores de irak4
MX2016014190A (es) Herbicidas de piridazinona.
ECSP14020586A (es) Composición para el control de plagas que incluye un derivado de iminopiridina novedoso
AR107488A1 (es) Compuestos de benzopirazol y análogos de éstos
AR092347A1 (es) Derivados de azaindol
AR098872A1 (es) Moduladores de tetrahidropiridopirazinas de gpr6
AR106652A1 (es) Compuestos para tratar la esclerosis lateral amiotrófica
CL2017000103A1 (es) Derivados de bis(aril)catecol como herbicidas
AR108876A1 (es) Formulaciones y composiciones de análogos de hidroximetionina y procesos para preparar las formulaciones
AR116695A1 (es) Los neuroesteroides y sus métodos de uso
AR099828A1 (es) Uso de oxotetrahidroquinolinilsulfonamidas sustituidas o sus sales para aumentar la tolerancia al estrés en plantas
MX2018009500A (es) Sal de maleato de agonista de tlr7, sus formas cristalinas c, d y e, sus metodos de preparacion y usos de la sal de maleato y formas cristalinas.
CR20170134A (es) Método para preparar 2´-o-fucosil-lactosa
AR102246A1 (es) Compuestos aromáticos sustituidos y composiciones farmacéuticas para la prevención y tratamiento de osteoporosis, usos
CO2020001471A2 (es) Compuesto pentacíclico
AR099690A1 (es) Ureas asimétricas p-sustituidas como moduladoras de la actividad de ghrelina
MX2021002260A (es) Compuestos utiles como moduladores de la autofagia mediada por chaperonas.
AR072119A1 (es) Productos que son compuestos derivados de pirroloindol inhibidores de hsp90, composiciones farmaceuticas que los contienen; utilizacion de los compuestos para la preparacion de medicamentos; dichos medicamentos constituidos por los compuestos activos e intermediarios de sintesis de dichos compuestos
AR117989A1 (es) Inhibidores de o-glucoproteína-2-acetamido-2-desoxi-3-d-glucopiranosidasa de éter bicíclico
AR092088A1 (es) Compuestos de pirazol-carboxamida, composiciones y metodos de uso

Legal Events

Date Code Title Description
FB Suspension of granting procedure